

- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. *CA Cancer J Clin* 2009;59:225–249.
- Rydholm A, Berg NO. Size, site and clinical incidence of lipoma. Factors in the differential diagnosis of lipoma and sarcoma. *Acta Orthop Scand* 1983;54:929–934.
- Levi F, La Vecchia C, Randimbison L, et al. Descriptive epidemiology of soft tissue sarcomas in Vaud, Switzerland. *Eur J Cancer* 1999;35:1711–1716.
- Ross JA, Severson RK, Davis S, et al. Trends in the incidence of soft tissue sarcomas in the United States from 1973 through 1987. *Cancer* 1993;72:486–490.
- Rydholm A, Berg NO, Gullberg B, et al. Epidemiology of soft-tissue sarcoma in the locomotor system. A retrospective population-based study of the interrelationships between clinical and morphologic variables. *Acta Pathol Microbiol Immunol Scand A* 1984;92:363–374.
- Storm HH. Cancers of the soft tissues. *Cancer Surv* 1994;19–20:197–217.
- Toro JR, Travis LB, Wu HJ, et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. *Int J Cancer* 2006;119:2922–2930.
- Mastrangelo C, Coindre JM, Ducimetiere F, et al. Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions. *Cancer* 2012;118:5339–5348.
- Wu X, Groves FD, McLaughlin CC, et al. Cancer incidence patterns among adolescents and young adults in the United States. *Cancer Causes Control* 2005;16:309–320.
- Bridge JA, Mertens F. Tumors of soft tissue: introduction. In: Fletcher CDM, Bridge JA, Hogendoom P, et al., eds. *WHO Classification of Tumours of Soft Tissue and Bone*. 4th ed. Lyon, France: IARC Press; 2013:14–18.
- Evans DG, Baser ME, McCaughan J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. *J Med Genet* 2002;39:311–314.
- Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science* 1990;250:1233–1238.
- Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. *Semin Oncol* 1997;24:504–514.
- Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. *J Clin Oncol* 2005;23:2272–2279.
- Fletcher O, Easton D, Anderson K, et al. Lifetime risks of common cancers among retinoblastoma survivors. *J Natl Cancer Inst* 2004;96:357–363.
- Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. *Cancer* 1948;1:64–81.
- Muller R, Hajdu SL, Brennan MF. Lymphangiosarcoma associated with chronic filarial lymphedema. *Cancer* 1987;59:179–183.
- Woodward AH, Ivins JC, Soule EH. Lymphangiosarcoma arising in chronic lymphedematous extremities. *Cancer* 1972;30:562–572.
- Schreiber H, Barry FM, Russell WC, et al. Stewart-Treves syndrome. A lethal complication of postmastectomy lymphedema and regional immune deficiency. *Arch Surg* 1979;114:82–85.
- Henderson TO, Whittion J, Stovall M, et al. Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. *J Natl Cancer Inst* 2007;99:300–308.
- Huang J, Mackillop WJ. Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. *Cancer* 2001;92:172–180.
- Kirova YM, Gambotti L, De Rycke Y, et al. Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review. *Int J Radiat Oncol Biol Phys* 2007;68:359–363.
- Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. *J Natl Cancer Inst* 2005;97:1354–1365.
- Gladdy RA, Qin LX, Moraco N, et al. Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas? *J Clin Oncol* 2010;28:2064–2069.
- Virtanen A, Pukkala E, Auvinen A. Incidence of bone and soft tissue sarcoma after radiotherapy: a cohort study of 295,712 Finnish cancer patients. *Int J Cancer* 2006;118:1017–1021.
- Fong Y, Rosen PP, Brennan MF. Multifocal desmoids. *Surgery* 1993;114:902–906.
- Visuri T, Pukkala E, Pulkkinen P, et al. Decreased cancer risk in patients who have been operated on with total hip and knee arthroplasty for primary osteoarthritis: a meta-analysis of 6 Nordic cohorts with 73,000 patients. *Acta Orthop Scand* 2003;74:351–360.
- Hoppin JA, Tolbert PE, Herrick RF, et al. Occupational chlorophenol exposure and soft tissue sarcoma risk among men aged 30–60 years. *Am J Epidemiol* 1998;148:693–703.
- Fingerhut MA, Halperin WE, Marlow DA, et al. Cancer mortality in workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. *N Engl J Med* 1991;324:212–218.
- Steenland K, Piacitelli L, Daddens J, et al. Cancer, heart disease, and diabetes in workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. *J Natl Cancer Inst* 1999;91:779–786.
- Smith AH, Pearce NE, Fisher DO, et al. Soft tissue sarcoma and exposure to phenoxylherbicides and chlorophenols in New Zealand. *J Natl Cancer Inst* 1984;73:1111–1117.
- Kang H, Enzinger FM, Breslin P, et al. Soft tissue sarcoma and military service in Vietnam: a case-control study. *J Natl Cancer Inst* 1987;79:693–699.
- The association of selected cancers with service in the US military in Vietnam. II. Soft-tissue and other sarcomas. The Selected Cancers Cooperative Study Group. *Arch Intern Med* 1990;150:2485–2492.
- Tuomisto J, Pekkanen J, Kiviranta H, et al. Dioxin cancer risk—example of hormesis? *Dose Response* 2006;3:332–341.
- Tuomisto JT, Pekkanen J, Kiviranta H, et al. Soft-tissue sarcoma and dioxin: a case-control study. *Int J Cancer* 2004;108:893–900.
- Fletcher CDM, Bridge JA, Hogendoom P, et al., eds. *WHO Classification of Tumours of Soft Tissue and Bone*. 4th ed. Lyon, France: IARC Press; 2013.
- Dalal KM, Kattan MW, Antonescu CR, et al. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. *Ann Surg* 2006;244:381–391.
- Eilber FC, Eilber FR, Eckardt J, et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. *Ann Surg* 2004;240:686–695.
- Fiore M, Grosso F, Lo Vullo S, et al. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. *Cancer* 2007;109:2522–2531.
- Singer S, Antonescu CR, Riedel E, et al. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. *Ann Surg* 2003;238:358–370.
- Fletcher CD, Gustafson P, Rydholm A, et al. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. *J Clin Oncol* 2001;19:3045–3050.
- Vanni R, Marras S, Faa G, et al. Chromosome instability in elastofibroma. *Cancer Genet Cytogenet* 1999;111:182–183.
- McComb EN, Feely MG, Neff JR, et al. Cytogenetic instability, predominantly involving chromosome 1, is characteristic of elastofibroma. *Cancer Genet Cytogenet* 2001;126:68–72.
- Chandrasekar CR, Grimer RJ, Carter SR, et al. Elastofibroma dorsi: an uncommon benign pseudotumour. *Sarcoma* 2008;2008:756565.
- Nagamine N, Nohara Y, Ito E. Elastofibroma in Okinawa. A clinicopathologic study of 170 cases. *Cancer* 1982;50:1794–1805.
- Erickson-Johnson MR, Chou MM, Evers BR, et al. Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion. *Lab Invest* 2011;91:1427–1433.
- Amary MF, Ye H, Berisha F, et al. Detection of USP6 gene rearrangement in nodular fasciitis: an important diagnostic tool. *Virchows Arch* 2013;463:97–98.
- Smith AJ, Lewis JJ, Merchant NB, et al. Surgical management of intra-abdominal desmoid tumours. *Br J Surg* 2000;87:608–613.
- Reitamo JJ, Hayry P, Nykyri E, et al. The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. *Am J Clin Pathol* 1982;77:665–673.
- Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. *Am J Pathol* 2008;173:1518–1527.
- Gardner EJ. Follow-up study of a family group exhibiting dominant inheritance for a syndrome including intestinal polyps, osteomas, fibromas and epidermal cysts. *Am J Hum Genet* 1962;14:376–390.
- Latchford A, Volikos E, Johnson V, et al. APC mutations in FAP-associated desmoid tumours are non-random but not “just right.” *Hum Mol Genet* 2007;16:78–82.
- O'Brien KP, Seroussi E, Dal Cin P, et al. Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. *Genes Chromosomes Cancer* 1998;23:187–193.
- Fiore M, Miceli R, Mussi C, et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. *J Clin Oncol* 2005;23:7669–7675.
- Fields RC, Hameed M, Qin LX, et al. Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. *Ann Surg Oncol* 2011;18:328–336.
- Farma JM, Ammori JB, Zager JS, et al. Dermatofibrosarcoma protuberans: how wide should we resect? *Ann Surg Oncol* 2010;17:2112–2118.
- Mendenhall WM, Zlotecki RA, Scarborough MT. Dermatofibrosarcoma protuberans. *Cancer* 2004;101:2503–2508.
- Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. *Clin Cancer Res* 2008;14:2717–2725.
- Maki RG, Awan RA, Dixon RH, et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. *Int J Cancer* 2002;100:623–626.
- McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. *J Clin Oncol* 2005;23:866–873.
- Rubin BP, Schuetz SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. *J Clin Oncol* 2002;20:3586–3591.

62. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. *J Clin Oncol* 2010;28:1772–1779.
63. Bowne WB, Antonescu CR, Leung DH, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. *Cancer* 2000;88:2711–2720.
64. Su LD, Atayde-Perez A, Sheldon S, et al. Inflammatory myofibroblastic tumor: cytogenetic evidence supporting clonal origin. *Mod Pathol* 1998;11:364–368.
65. Griffin CA, Hawkins AL, Dvorak C, et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. *Cancer Res* 1999;59:2776–2780.
66. Bridge JA, Kanamori M, Ma Z, et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. *Am J Pathol* 2001;159:411–415.
67. Kazmierczak B, Dal Cin P, Sciort R, et al. Inflammatory myofibroblastic tumor with HMGIC rearrangement. *Cancer Genet Cytogenet* 1999;112:156–160.
68. Coffin CM, Patel A, Perkins S, et al. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. *Mod Pathol* 2001;14:569–576.
69. Cook JR, Dehner LP, Collins MH, et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. *Am J Surg Pathol* 2001;25:1364–1371.
70. Kakitsubata Y, Theodorou SJ, Theodorou DJ, et al. Myofibroblastic inflammatory tumor of the lung: CT findings with pathologic correlation. *Comput Med Imaging Graph* 2007;31:607–613.
71. Rasalkar DD, Chu WC, To KF, et al. Radiological appearance of inflammatory myofibroblastic tumour. *Pediatr Blood Cancer* 2010;54:1029–1031.
72. Alaggio R, Cecchetto G, Bisogno G, et al. Inflammatory myofibroblastic tumors in childhood: a report from the Italian Cooperative Group studies. *Cancer* 2010;116:216–226.
73. Mosse YP, Wood A, Maris JM. Inhibition of ALK signaling for cancer therapy. *Clin Cancer Res* 2009;15:5609–5614.
74. Tuveson DA, Fletcher JA. Signal transduction pathways in sarcoma as targets for therapeutic intervention. *Curr Opin Oncol* 2001;13:249–255.
75. Webb TR, Slavish J, George RE, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. *Expert Rev Anticancer Ther* 2009;9:331–356.
76. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. *N Engl J Med* 2010;363:1727–1733.
77. Mosse YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase I consortium study. *Lancet Oncol* 2013;14:472–480.
78. Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. *Nat Genet* 2013;45:180–185.
79. Chmielecki J, Crago AM, Rosenberg M, et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. *Nat Genet* 2013;45:131–132.
80. Demicco EG, Park MS, Araujo DM, et al. Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. *Mod Pathol* 2012;25:1298–1306.
81. Fukasawa Y, Takada A, Tateno M, et al. Solitary fibrous tumor of the pleura causing recurrent hypoglycemia by secretion of insulin-like growth factor II. *Pathol Int* 1998;48:47–52.
82. Lloyd RV, Erickson LA, Nascimento AG, et al. Neoplasms causing nonhypersulinemic hypoglycemia. *Endocr Pathol* 1999;10:291–297.
83. Perros P, Simpson J, Innes JA, et al. Non-islet cell tumour-associated hypoglycaemia: 111In-octreotide imaging and efficacy of octreotide, growth hormone and glucocorticosteroids. *Clin Endocrinol (Oxf)* 1996;44:727–731.
84. Wakami K, Tateyama H, Kawashima H, et al. Solitary fibrous tumor of the uterus producing high-molecular-weight insulin-like growth factor II and associated with hypoglycemia. *Int J Gynecol Pathol* 2005;24:79–84.
85. Stacchiotti S, Negri T, Palasini E, et al. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. *Mol Cancer Ther* 2010;9:1286–1297.
86. Valentin T, Fournier C, Penel N, et al. Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). *Invest New Drugs* 2013;31:1626–1627.
87. Bahrami A, Folpe AL. Adult-type fibrosarcoma: A reevaluation of 163 putative cases diagnosed at a single institution over a 48-year period. *Am J Surg Pathol* 2010;34:1504–1513.
88. Limon J, Szadowska A, Iliszko M, et al. Recurrent chromosome changes in two adult fibrosarcomas. *Genes Chromosomes Cancer* 1998;21:119–123.
89. Knezevich SR, McFadden DE, Tao W, et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. *Nat Genet* 1998;18:184–187.
90. Orbach D, Rey A, Cecchetto G, et al. Infantile fibrosarcoma: management based on the European experience. *J Clin Oncol* 2010;28:318–323.
91. Fletcher CD, Unni KK, Mertens F., eds. *World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone*. Lyon: IARC Press; 2002.
92. Hollowood K, Fletcher CD. Malignant fibrous histiocytoma: morphologic pattern or pathologic entity? *Semin Diagn Pathol* 1995;12:210–220.
93. Huang HY, Lal P, Qin J, et al. Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. *Hum Pathol* 2004;35:612–621.
94. Mentzel T, Calonje E, Wadden C, et al. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. *Am J Surg Pathol* 1996;20:391–405.
95. Merck C, Angervall L, Kindblom LG, et al. Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastic-histiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis. *Acta Pathol Microbiol Immunol Scand Suppl* 1983;282:1–40.
96. Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. *Cancer* 1977;39:1672–1685.
97. Mutter RW, Singer S, Zhang Z, et al. The enigma of myxofibrosarcoma of the extremity. *Cancer* 2012;118:518–527.
98. Fletcher CD. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. *Am J Surg Pathol* 1992;16:213–228.
99. Cheng H, Clarkson PW, Gao D, et al. Therapeutic antibodies targeting CSF1 impede macrophage recruitment in a xenograft model of tenosynovial giant cell tumor. *Sarcoma* 2010;2010:174528.
100. Cupp JS, Miller MA, Montgomery KD, et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. *Am J Surg Pathol* 2007;31:970–976.
101. West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. *Proc Natl Acad Sci U S A* 2006;103:690–695.
102. Li CF, Wang JW, Huang WW, et al. Malignant diffuse-type tenosynovial giant cell tumors: a series of 7 cases comparing with 24 benign lesions with review of the literature. *Am J Surg Pathol* 2008;32:587–599.
103. Griffin AM, Ferguson PC, Catton CN, et al. Long-term outcome of the treatment of high-risk tenosynovial giant cell tumor/pigmented villonodular synovitis with radiotherapy and surgery. *Cancer* 2012;118:4901–4909.
104. O'Sullivan B, Cummings B, Catton C, et al. Outcome following radiation treatment for high-risk pigmented villonodular synovitis. *Int J Radiat Oncol Biol Phys* 1995;32:777–786.
105. Blay JY, El Sayadi H, Thiesse P, et al. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). *Ann Oncol* 2008;19:821–822.
106. Cassier PA, Gelderblom H, Stacchiotti S, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. *Cancer* 2012;118:1649–1655.
107. Mentzel T, Wiesner T, Cerroni L, et al. Malignant dermatofibroma: clinicopathological, immunohistochemical, and molecular analysis of seven cases. *Mod Pathol* 2013;26:256–267.
108. Willen H, Akerman M, Dal Cin P, et al. Comparison of chromosomal patterns with clinical features in 165 lipomas: a report of the CHAMP study group. *Cancer Genet Cytogenet* 1998;102:46–49.
109. Dal Cin P, Sciort R, Polito P, et al. Lesions of 13q may occur independently of deletion of 16q in spindle cell/pleomorphic lipomas. *Histopathology* 1997;31:222–225.
110. El-Hashemite N, Zhang H, Henske EP, et al. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. *Lancet* 2003;361:1348–1349.
111. Green AJ, Johnson PH, Yates JR. The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor. *Hum Mol Genet* 1994;3:1833–1834.
112. Green AJ, Smith M, Yates JR. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. *Nat Genet* 1994;6:193–196.
113. Kenerson H, Folpe AL, Takayama TK, et al. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. *Hum Pathol* 2007;38:1361–1371.
114. Lesma E, Sirchia SM, Ancona S, et al. The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells. *Am J Pathol* 2009;174:2150–2159.
115. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. *N Engl J Med* 2008;358:140–151.
116. Krishnan A, Sandrini A, Yates D. Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment. *J Heart Lung Transplant* 2008;27:1268.
117. Wienecke R, Fackler I, Linsenmaier U, et al. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. *Am J Kidney Dis* 2006;48:e27–29.
118. Crago AM, Socci ND, DeCarolis P, et al. Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability. *Clin Cancer Res* 2012;18:1334–1340.
119. Kooby DA, Antonescu CR, Brennan MF, et al. Atypical lipomatous tumor/well-differentiated liposarcoma of the extremity and trunk wall: importance of histological subtype with treatment recommendations. *Ann Surg Oncol* 2004;11:78–84.
120. Antonescu CR, Elahi A, Humphrey M, et al. Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma: absence in predominantly myxoid well-differentiated liposarcomas. *J Mol Diagn* 2000;2:132–138.

121. Antonescu CR, Tschernyavsky SJ, Decuseara R, et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. *Clin Cancer Res* 2001;7:3977–3987.
122. Schwab JH, Boland PJ, Antonescu C, et al. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. *Cancer* 2007;110:1815–1822.
123. Pitson G, Robinson P, Wilke D, et al. Radiation response: an additional unique signature of myxoid liposarcoma. *Int J Radiat Oncol Biol Phys* 2004;60:522–526.
124. Germano G, Frapollì R, Simone M, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. *Cancer Res* 2010;70:2235–2244.
125. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. *Lancet Oncol* 2007;8:595–602.
126. Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. *Ann Oncol* 2009;20:1439–1444.
127. Taylor BS, Barretina J, Socci ND, et al. Functional copy-number alterations in cancer. *PLoS One* 2008;3:e3179.
128. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. *J Clin Oncol* 2007;25:2755–2763.
129. Ono M, Yin P, Navarro A, et al. Paracrine activation of WNT/beta-catenin pathway in uterine leiomyoma stem cells promotes tumor growth. *Proc Natl Acad Sci U S A* 2013;110:17053–17058.
130. Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy. *Nat Genet* 2010;42:715–721.
131. Perot G, Croce S, Ribeiro A, et al. MED12 alterations in both human benign and malignant uterine soft tissue tumors. *PLoS One* 2012;7:e40015.
132. Hollenbeck ST, Grobmyer SR, Kent KC, et al. Surgical treatment and outcomes of patients with primary inferior vena cava leiomyosarcoma. *J Am Coll Surg* 2003;197:575–579.
133. Gladly RA, Qin LX, Moraco N, et al. Predictors of survival and recurrence in primary leiomyosarcoma. *Ann Surg Oncol* 2013;20:1851–1857.
134. Kraft S, Fletcher CD. Atypical intradermal smooth muscle neoplasms: clinicopathologic analysis of 84 cases and a reappraisal of cutaneous “leiomyosarcoma.” *Am J Surg Pathol* 2011;35:599–607.
135. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. *J Clin Oncol* 1995;13:610–630.
136. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. *J Clin Oncol* 2001;19:3091–3102.
137. Belyea BC, Naini S, Bentley RC, et al. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis. *Clin Cancer Res* 2011;17:7324–7336.
138. Zibat A, Missiaglia E, Rosenberger A, et al. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. *Oncogene* 2010;29:6323–6330.
139. Roma J, Masia A, Reventos J, et al. Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro. *Clin Cancer Res* 2011;17:505–513.
140. Shukla N, Ameur N, Yilmaz I, et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. *Clin Cancer Res* 2012;18:748–757.
141. La Quaglia MP, Heller G, Ghavimi F, et al. The effect of age at diagnosis on outcome in rhabdomyosarcoma. *Cancer* 1994;73:109–117.
142. Esnaola NF, Rubin BP, Baldini EH, et al. Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. *Ann Surg* 2001;234:215–223.
143. Davicioni E, Anderson MJ, Finckenstein FG, et al. Molecular classification of rhabdomyosarcoma—genotypic and phenotypic determinants of diagnosis: a report from the Children’s Oncology Group. *Am J Pathol* 2009;174:550–564.
144. Davis RJ, D’Cruz CM, Lovell MA, et al. Fusion of PAX7 to FKHR by the variant t(1;3)(p36;q14) translocation in alveolar rhabdomyosarcoma. *Cancer Res* 1994;54:2869–2872.
145. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children’s oncology group. *J Clin Oncol* 2002;20:2672–2679.
146. Williamson D, Missiaglia E, de Reynies A, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. *J Clin Oncol* 2010;28:2151–2158.
147. Duan F, Smith LM, Gustafson DM, et al. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children’s Oncology Group. *Genes Chromosomes Cancer* 2012;51:662–674.
148. Shern JF, Chen L, Chmielecki J, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. *Cancer Discov* 2014;4:216–231.
149. Furlong MA, Mentzel T, Fanburg-Smith JC. Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers. *Mod Pathol* 2001;14:595–603.
150. Mehrabi A, Kashfi A, Fonouni H, et al. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. *Cancer* 2006;107:2108–2121.
151. Tanas MR, Shoner A, Oliveira AM, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. *Sci Transl Med* 2011;3:98ra82.
152. Errani C, Zhang L, Sung YS, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. *Genes Chromosomes Cancer* 2011;50:644–653.
153. Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. *Ann Oncol* 2013;24:257–263.
154. Meis-Kindblom JM, Kindblom LG. Angiosarcoma of soft tissue: a study of 80 cases. *Am J Surg Pathol* 1998;22:683–697.
155. Lindet C, Neuville A, Penel N, et al. Localised angiosarcomas: the identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO). *Eur J Cancer* 2013;49:369–376.
156. Torres KE, Ravi V, Kin K, et al. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. *Ann Surg Oncol* 2013;20:1267–1274.
157. D’Angelo SP, Antonescu CR, Kuk D, et al. High-risk features in radiation-associated breast angiosarcomas. *Br J Cancer* 2013;109:2340–2346.
158. Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. *J Clin Oncol* 2008;26:5269–5274.
159. Budd GT. Management of angiosarcoma. *Curr Oncol Rep* 2002;4:515–519.
160. Guo T, Zhang L, Chang NE, et al. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. *Genes Chromosomes Cancer* 2011;50:25–33.
161. Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. *Cancer Res* 2009;69:7175–7179.
162. Folpe AL, Fanburg-Smith JC, Miettinen M, et al. Atypical and malignant glomus tumors: analysis of 52 cases, with a proposal for the reclassification of glomus tumors. *Am J Surg Pathol* 2001;25:1–12.
163. Schiefer TK, Parker WL, Anakwenze OA, et al. Extradigital glomus tumors: a 20-year experience. *Mayo Clin Proc* 2006;81:1337–1344.
164. Brouillard P, Ghassib M, Penington A, et al. Four common glomulin mutations cause two thirds of glomovenous malformations (“familial glomangiomas”): evidence for a founder effect. *J Med Genet* 2005;42:e13.
165. Brems H, Park C, Maertens O, et al. Glomus tumors in neurofibromatosis type 1: genetic, functional, and clinical evidence of a novel association. *Cancer Res* 2009;69:7393–7401.
166. White W, Shiu MH, Rosenblum MK, et al. Cellular schwannoma. A clinicopathologic study of 57 patients and 58 tumors. *Cancer* 1990;66:1266–1275.
167. Kurtkaya-Yapici O, Scheithauer BW, Woodruff JM, et al. Schwannoma with rhabdomyoblastic differentiation: a unique variant of malignant triton tumor. *Am J Surg Pathol* 2003;27:848–853.
168. Zou C, Smith KD, Liu J, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. *Ann Surg* 2009;249:1014–1022.
169. Brekke HR, Kolberg M, Skotheim RI, et al. Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. *Neuro Oncol* 2009;11:514–528.
170. Hagel C, Zils U, Peiper M, et al. Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. *J Neurooncol* 2007;82:187–192.
171. Porter DE, Prasad V, Foster L, et al. Survival in malignant peripheral nerve sheath tumours: a comparison between sporadic and neurofibromatosis type 1-associated tumours. *Sarcoma* 2009;2009:756395.
172. Kroep JR, Ouali M, Gelderblom H, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. *Ann Oncol* 2011;22:207–214.
173. Gudena V, Verma N, Post G, et al. Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review. *Cancer Biol Ther* 2008;7:810–813.
174. Maki RG, D’Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. *J Clin Oncol* 2009;27:3133–3140.
175. Goldstein-Jackson SY, Gosheger G, Dellling G, et al. Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma. *J Cancer Res Clin Oncol* 2005;131:520–526.
176. van Roggen JF, McMenamin ME, Fletcher CD. Cellular myxoma of soft tissue: a clinicopathological study of 38 cases confirming indolent clinical behaviour. *Histopathology* 2001;39:287–297.
177. Okamoto S, Hisaoka M, Ushijima M, et al. Activating Gs(alpha) mutation in intramuscular myxomas with and without fibrous dysplasia of bone. *Virchows Arch* 2000;437:133–137.

178. Delaney D, Diss TC, Presneau N, et al. GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma. *Mod Pathol* 2009;22:718–724.
179. Medeiros F, Erickson-Johnson MR, Keeney GL, et al. Frequency and characterization of HMGA2 and HMGA1 rearrangements in mesenchymal tumors of the lower genital tract. *Genes Chromosomes Cancer* 2007;46:981–990.
180. Hornick JL, Fletcher CD. PECOMA: what do we know so far? *Histopathology* 2006;48:75–82.
181. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangiomyomatosis. *Proc Natl Acad Sci U S A* 2000;97:6085–6090.
182. Smolarek TA, Wessner LL, McCormack FX, et al. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. *Am J Hum Genet* 1998;62:810–815.
183. Paul E, Thiele E. Efficacy of sirolimus in treating tuberous sclerosis and lymphangiomyomatosis. *N Engl J Med* 2008;358:190–192.
184. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. *J Clin Oncol* 2010;28:835–840.
185. Wolff N, Kabbani W, Bradley T, et al. Sirolimus and temsirolimus for epithelioid angiomyolipoma. *J Clin Oncol* 2010;28:e65–e68.
186. Lewis JJ, Antonescu CR, Leung DH, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. *J Clin Oncol* 2000;18:2087–2094.
187. Cancer Genome Anatomy Project. Mitelman database of chromosome aberrations and gene fusions in cancer. <http://cgap.nci.nih.gov/Chromosomes/Mitelman>. Accessed April 15, 2010.
188. Ladanyi M. Fusions of the SYT and SSX genes in synovial sarcoma. *Oncogene* 2001;20:5755–5762.
189. Ren T, Lu Q, Guo W, et al. The clinical implication of SS18-SSX fusion gene in synovial sarcoma. *Br J Cancer* 2013;109:2279–2285.
190. Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. *Cancer Res* 2002;62:135–140.
191. Lagarde P, Przybyl J, Brulard C, et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. *J Clin Oncol* 2013;31:608–615.
192. Filion C, Motoi T, Olshen AB, et al. The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARC nuclear receptor gene. *J Pathol* 2009;217:83–93.
193. Stenman G, Andersson H, Mandahl N, et al. Translocation t(9;22)(q22;q12) is a primary cytogenetic abnormality in extraskeletal myxoid chondrosarcoma. *Int J Cancer* 1995;62:398–402.
194. Turc-Carel C, Dal Cin P, Rao U, et al. Recurrent breakpoints at 9q31 and 22q12.2 in extraskeletal myxoid chondrosarcoma. *Cancer Genet Cytogenet* 1988;30:145–150.
195. Bjerkehagen B, Dietrich C, Reed W, et al. Extraskeletal myxoid chondrosarcoma: multimodal diagnosis and identification of a new cytogenetic subgroup characterized by t(9;17)(q22;q11). *Virchows Arch* 1999;435:524–530.
196. Antonescu CR, Argani P, Eirlanson RA, et al. Skeletal and extraskeletal myxoid chondrosarcoma: a comparative clinicopathologic, ultrastructural, and molecular study. *Cancer* 1998;83:1504–1521.
197. Drilon AD, Popat S, Bhuchar G, et al. Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy. *Cancer* 2008;113:3364–3371.
198. Stacchiotti S, Dagrada GP, Morosi C, et al. Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. *Clin Sarcoma Res* 2012;2:22.
199. Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. *Oncogene* 2001;20:48–57.
200. Bu X, Bernstein L. A proposed explanation for female predominance in alveolar soft part sarcoma. Noninactivation of X; autosome translocation fusion gene? *Cancer* 2005;103:1245–1253.
201. Lieberman PH, Brennan MF, Kimmel M, et al. Alveolar soft-part sarcoma. A clinico-pathologic study of half a century. *Cancer* 1989;63:1–13.
202. Porter CA, Jr., Ho V, Patel SR, et al. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. *Cancer* 2001;91:585–591.
203. Reichardt P, Lindner T, Pink D, et al. Chemotherapy in alveolar soft part sarcomas. What do we know? *Eur J Cancer* 2003;39:1511–1516.
204. Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. *Cancer Res* 2007;67:919–929.
205. National Institutes of Health. ClinicalTrials.gov: CREATE: Cross-tumoral Phase 2 with Crizotinib. <http://www.clinicaltrials.gov/ct2/show/NCT01524926>. Accessed January 15, 2014.
206. Stacchiotti S, Tamborini E, Marrari A, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. *Clin Cancer Res* 2009;15:1096–1104.
207. Stacchiotti S, Negri T, Zaffaroni N, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. *Ann Oncol* 2011;22:1682–1690.
208. Azizi AA, Haberler C, Czech T, et al. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. *Lancet Oncol* 2006;7:521–523.
209. Guillou L, Wadden C, Coindre JM, et al. “Proximal-type” epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series. *Am J Surg Pathol* 1997;21:130–146.
210. Levy A, Le Pechoux C, Terrier P, et al. Epithelioid sarcoma: need for a multimodal approach to maximize the chances of curative conservative treatment. *Ann Surg Oncol* 2014;21:269–276.
211. Chase DR, Enzinger FM. Epithelioid sarcoma. Diagnosis, prognostic indicators, and treatment. *Am J Surg Pathol* 1985;9:241–263.
212. Chbani L, Guillou L, Terrier P, et al. Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group. *Am J Clin Pathol* 2009;131:222–227.
213. Hasegawa T, Matsuno Y, Shimoda T, et al. Proximal-type epithelioid sarcoma: a clinicopathologic study of 20 cases. *Mod Pathol* 2001;14:655–663.
214. Rekihi B, Gorad BD, Chinoy RF. Clinicopathological features with outcomes of a series of conventional and proximal-type epithelioid sarcomas, diagnosed over a period of 10 years at a tertiary cancer hospital in India. *Virchows Arch* 2008;453:141–153.
215. Xie X, Ghadimi MP, Young ED, et al. Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. *Clin Cancer Res* 2011;17:5901–5912.
216. Modena P, Luaili E, Facchinetti F, et al. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. *Cancer Res* 2005;65:4012–4019.
217. Meis-Kindblom JM. Clear cell sarcoma of tendons and aponeuroses: a historical perspective and tribute to the man behind the entity. *Adv Anat Pathol* 2006;13:286–292.
218. Segal NH, Pavlidis P, Noble WS, et al. Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. *J Clin Oncol* 2003;21:1775–1781.
219. Peulve P, Michot C, Vannier JP, et al. Clear cell sarcoma with t(12;22)(q13-14;q12). *Genes Chromosomes Cancer* 1991;3:400–402.
220. Davis IJ, McFadden AW, Zhang Y, et al. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. *Cancer Res* 2010;70:639–645.
221. van Akkooi AC, Verhoef C, van Geel AN, et al. Sentinel node biopsy for clear cell sarcoma. *Eur J Surg Oncol* 2006;32:996–999.
222. Mir O, Boudou-Rouquette P, Larousserie F, et al. Objective response to sorafenib in advanced clear-cell sarcoma. *Ann Oncol* 2012;23:807–809.
223. Stacchiotti S, Grosso F, Negri T, et al. Tumor response to sunitinib malate observed in clear-cell sarcoma. *Ann Oncol* 2010;21:1130–1131.
224. Chang F. Desmoplastic small round cell tumors: cytologic, histologic, and immunohistochemical features. *Arch Pathol Lab Med* 2006;130:728–732.
225. Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. *Cancer Res* 1994;54:2837–2840.
226. Lee SB, Kolquist KA, Nichols K, et al. The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. *Nat Genet* 1997;17:309–313.
227. Quaglia MP, Brennan MF. The clinical approach to desmoplastic small round cell tumor. *Surg Oncol* 2000;9:77–81.
228. Stuart-Buttle CE, Smart CJ, Pritchard S, et al. Desmoplastic small round cell tumour: a review of literature and treatment options. *Surg Oncol* 2008;17:107–112.
229. van Unnik JA, Coindre JM, Contesso C, et al. Grading of soft tissue sarcomas: experience of the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer* 1993;29A:2089–2093.
230. Broders A, Hargrave R, Meyerding H. Pathological features of soft tissue fibrosarcoma with special reference to the grading of its malignancy. *Surg Gynecol Obstet* 1939;69:267–280.
231. Costa J, Wesley RA, Glatstein E, et al. The grading of soft tissue sarcomas. Results of a clinicopathologic correlation in a series of 163 cases. *Cancer* 1984;53:530–541.
232. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. *J Clin Oncol* 1997;15:350–362.
233. Hajdu S. History and classification of soft tissue tumors. In: Hajdu S, ed. *Pathology of Soft Tissue Tumors*. Philadelphia: Lea & Febiger; 1979:1–55.
234. Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. *Int J Cancer* 1984;33:37–42.
235. Alvegard TA, Berg NO. Histopathology peer review of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience. *J Clin Oncol* 1989;7:1845–1851.
236. Coindre J, Trojani M, Contesso G, et al. Reproducibility of a histopathologic grading system for adult soft-tissue sarcoma. *Cancer* 1986;58:306–309.
237. Presant CA, Russell WO, Alexander RW, et al. Soft-tissue and bone sarcoma histopathology peer review: the frequency of disagreement in diagnosis and the need for second pathology opinions. The Southeastern Cancer Study Group experience. *J Clin Oncol* 1986;4:1658–1661.

238. Recommendations for reporting soft tissue sarcomas. Association of Directors of Anatomic and Surgical Pathology. *Am J Clin Pathol* 1999;111:594-598.
239. Pisters PW, Leung DH, Woodruff J, et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. *J Clin Oncol* 1996;14:1679-1689.
240. Hasegawa T, Yamamoto S, Nojima T, et al. Validity and reproducibility of histologic diagnosis and grading for adult soft-tissue sarcomas. *Hum Pathol* 2002;33:111-115.
241. Hasegawa T, Yamamoto S, Yokoyama R, et al. Prognostic significance of grading and staging systems using MIB-1 score in adult patients with soft tissue sarcoma of the extremities and trunk. *Cancer* 2002;95:843-851.
242. Drobniak M, Latres E, Pollack D, et al. Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. *J Natl Cancer Inst* 1994;86:549-554.
243. Chibon F, Lagarde P, Salas S, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. *Nat Med* 2010;16:781-787.
244. Italiano A, Lagarde P, Brulard C, et al. Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics. *Clin Cancer Res* 2013;19:1190-1196.
245. Clark J, Rocques PJ, Crew AJ, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. *Nat Genet* 1994;7:502-508.
246. Crozat A, Aman P, Mandahl N, et al. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. *Nature* 1993;363:640-644.
247. Knight JC, Renwick PJ, Dal Cin P, et al. Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. *Cancer Res* 1995;55:24-27.
248. Khan J, Wei JS, Ringner M, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. *Nat Med* 2001;7:673-679.
249. Shiraki M, Enterline HT, Brooks JJ, et al. Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group (ECOG) experience. *Cancer* 1989;64:484-490.
250. Ray-Coquard I, Montesco MC, Coindre JM, et al. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. *Ann Oncol* 2012;23:2442-2449.
251. Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: report of the Radiology Diagnostic Oncology Group. *Radiology* 1997;202:237-246.
252. Buck AK, Herrmann K, Buschenfelde CM, et al. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine. *Clin Cancer Res* 2008;14:2970-2977.
253. Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, et al. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. *J Nucl Med* 2001;42:713-720.
254. Schulte M, Brecht-Krauss D, Heymer B, et al. Grading of tumors and tumor-like lesions of bone: evaluation by FDG PET. *J Nucl Med* 2000;41:1695-1701.
255. Benz MR, Allen-Auerbach MS, Eilber FC, et al. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. *J Nucl Med* 2008;49:1579-1584.
256. Evilevitch V, Weber WA, Tap WD, et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. *Clin Cancer Res* 2008;14:715-720.
257. Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. *Cancer* 2005;103:339-348.
258. Herrmann K, Benz MR, Czernin J, et al. 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. *Clin Cancer Res* 2012;18:2024-2031.
259. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, et al. Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. *J Nucl Med* 2010;51:551-558.
260. Gadd MA, Casper ES, Woodruff JM, et al. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. *Ann Surg* 1993;218:705-712.
261. Cheng EY, Springfield DS, Mankin HJ. Frequent incidence of extrapulmonary sites of initial metastasis in patients with liposarcoma. *Cancer* 1995;75:1120-1127.
262. Fong Y, Coit DG, Woodruff JM, et al. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. *Ann Surg* 1993;217:72-77.
263. Behranwala KA, A'Hern R, Omar AM, et al. Prognosis of lymph node metastasis in soft tissue sarcoma. *Ann Surg Oncol* 2004;11:714-719.
264. Margaritora S, Porziella V, D'Andrilli A, et al. Pulmonary metastases: can accurate radiological evaluation avoid thoracotomy approach? *Eur J Cardiothorac Surg* 2002;21:1111-1114.
265. Tateishi U, Yamaguchi U, Seki K, et al. Bone and soft-tissue sarcoma: pre-operative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. *Radiology* 2007;245:839-847.
266. Heslin MJ, Lewis JJ, Woodruff JM, et al. Core needle biopsy for diagnosis of extremity soft tissue sarcoma. *Ann Surg Oncol* 1997;4:425-431.
267. Rydholm A. Soft tissue lesions in adults: biopsy—yes or no? *Ann Oncol* 1992;3:S57-S58.
268. Edge SB, Byrd DR, Compton CC, et al., eds. *The AJCC Cancer Staging Manual*. 7th ed. New York: Springer; 2009.
269. Maki RG, Moraco N, Antonescu CR, et al. Toward better soft tissue sarcoma staging: building on american joint committee on cancer staging systems versions 6 and 7. *Ann Surg Oncol* 2013;20:3377-3383.
270. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. *J Clin Oncol* 2002;20:791-796.
271. Kattan MW, Heller G, Brennan MF. A competing-risks nomogram for sarcoma-specific death following local recurrence. *Stat Med* 2003;22:3515-3525.
272. Canter RJ, Qin LX, Maki RG, et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. *Clin Cancer Res* 2008;14:8191-8197.
273. Gold JS, Gonen M, Gutierrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. *Lancet Oncol* 2009;10:1045-1052.
274. Anaya DA, Lahat G, Wang X, et al. Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent. *Ann Oncol* 2010;21:397-402.
275. Ardoino I, Miceli R, Berselli M, et al. Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma. *Cancer* 2010;116:2429-2436.
276. Gronchi A, Miceli R, Shurell E, et al. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. *J Clin Oncol* 2013;31:1649-1655.
277. Cahlon O, Brennan MF, Jia X, et al. A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation. *Ann Surg* 2012;255:343-347.
278. Stojadinovic A, Leung DH, Allen P, et al. Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. *J Clin Oncol* 2002;20:4344-4352.
279. Lewis JJ, Leung D, Casper ES, et al. Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. *Arch Surg* 1999;134:190-194.
280. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. *J Clin Oncol* 2003;21:2719-2725.
281. Jaques DP, Coit DG, Hajdu SI, et al. Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. *Ann Surg* 1990;212:51-59.
282. Lewis JJ, Leung D, Woodruff JM, et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. *Ann Surg* 1998;228:355-365.
283. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. *Ann Surg* 1982;196:305-315.
284. Davis AM, Devlin M, Griffin AM, et al. Functional outcome in amputation versus limb sparing of patients with lower extremity sarcoma: a matched case-control study. *Arch Phys Med Rehabil* 1999;80:615-618.
285. Alektiar KM, Leung D, Zelefsky MJ, et al. Adjuvant radiation for stage II-B soft tissue sarcoma of the extremity. *J Clin Oncol* 2002;20:1643-1650.
286. Baldini EH, Goldberg J, Jenner C, et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. *J Clin Oncol* 1999;17:3252-3259.
287. Pisters PW, Pollock RE, Lewis VO, et al. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. *Ann Surg* 2007;246:675-681.
288. Noria S, Davis A, Kandel R, et al. Residual disease following unplanned excision of soft-tissue sarcoma of an extremity. *J Bone Joint Surg Am* 1996;78:650-655.
289. Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. *J Clin Oncol* 1996;14:859-868.
290. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. *J Clin Oncol* 1998;16:197-203.
291. Fabrizio PL, Stafford SL, Pritchard DJ. Extremity soft-tissue sarcomas selectively treated with surgery alone. *Int J Radiat Oncol Biol Phys* 2000;48:227-232.
292. Alektiar KM, Leung D, Zelefsky MJ, et al. Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity. *Ann Surg Oncol* 2002;9:48-56.
293. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. *Lancet* 2002;359:2235-2241.
294. O'Sullivan B, Davis A, Turcotte R, et al. Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma. *Proc Am Soc Clin Oncol* 2004;22:(abst 815).
295. Al-Absi E, Farrokhyar F, Sharma R, et al. A systematic review and meta-analysis of oncologic outcomes of pre- versus postoperative radiation in localized resectable soft-tissue sarcoma. *Ann Surg Oncol* 2010;17:1367-1374.

296. Davis AM, O'Sullivan B, Bell RS, et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. *J Clin Oncol* 2002;20:4472-4477.
297. Davis AM, O'Sullivan B, Turcotte R, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. *Radiother Oncol* 2005;75:48-53.
298. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. *Cancer Res* 1983;43:1488-1492.
299. Leibel SA, Fuks Z, Zelefsky MJ, et al. Intensity-modulated radiotherapy. *Cancer J* 2002;8:164-176.
300. O'Sullivan B, Ward I, Haycocks T, et al. Techniques to modulate radiotherapy toxicity and outcome in soft tissue sarcoma. *Curr Treat Options Oncol* 2003;4:453-464.
301. Alektiar KM, Hong L, Brennan MF, et al. Intensity modulated radiation therapy for primary soft tissue sarcoma of the extremity: preliminary results. *Int J Radiat Oncol Biol Phys* 2007;68:458-464.
302. Griffin AM, Euler CI, Sharpe MB, et al. Radiation planning comparison for superficial tissue avoidance in radiotherapy for soft tissue sarcoma of the lower extremity. *Int J Radiat Oncol Biol Phys* 2007;67:847-856.
303. O'Sullivan B, Griffin AM, Dickie CI, et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. *Cancer* 2013;119:1878-1884.
304. Alektiar KM, Brennan MF, Singer S. Local control comparison of adjuvant brachytherapy to intensity-modulated radiotherapy in primary high-grade sarcoma of the extremity. *Cancer* 2011;117:3229-3234.
305. Alektiar KM, Brennan MF, Healey JH, et al. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. *J Clin Oncol* 2008;26:3440-3444.
306. Wang D, Bosch W, Roberge D, et al. RTOG sarcoma radiation oncologists reach consensus on gross tumor volume and clinical target volume on computed tomographic images for preoperative radiotherapy of primary soft tissue sarcoma of extremity in Radiation Therapy Oncology Group studies. *Int J Radiat Oncol Biol Phys* 2011;81:e525-528.
307. Haas RL, Delaney TF, O'Sullivan B, et al. Radiotherapy for management of extremity soft tissue sarcomas: why, when, and where? *Int J Radiat Oncol Biol Phys* 2012;84:572-580.
308. White LM, Wunder JS, Bell RS, et al. Histologic assessment of peritumoral edema in soft tissue sarcoma. *Int J Radiat Oncol Biol Phys* 2005;61:1439-1445.
309. National Institutes of Health. ClinicalTrials.gov: Radiation therapy in treating patients who have undergone surgery for soft tissue sarcoma of the arms, hands, legs, or feet. <http://clinicaltrials.gov/ct2/show/NCT00423618>. Accessed May 1, 2010.
310. Delaney TF, Kepka L, Goldberg SI, et al. Radiation therapy for control of soft-tissue sarcomas resected with positive margins. *Int J Radiat Oncol Biol Phys* 2007;67:1460-1469.
311. Al Yami A, Griffin AM, Ferguson PC, et al. Positive surgical margins in soft tissue sarcoma treated with preoperative radiation: is a postoperative boost necessary? *Int J Radiat Oncol Biol Phys* 2010;77:1191-1197.
312. Pan E, Goldberg SI, Chen YL, et al. Role of postoperative radiation (RT) boost for soft tissue sarcomas with positive margins following preoperative RT and resection. *Int J Radiat Oncol Biol Phys* 2013;87:S65 [abstract].
313. Ormsby MV, Hilaris BS, Nori D, et al. Wound complications of adjuvant radiation therapy in patients with soft-tissue sarcomas. *Ann Surg* 1989;210:93-99.
314. Harrison LB, Franzese F, Gaynor JJ, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in the management of completely resected soft tissue sarcomas of the extremity and superficial trunk. *Int J Radiat Oncol Biol Phys* 1993;27:259-265.
315. Holloway CL, Delaney TF, Alektiar KM, et al. American Brachytherapy Society (ABS) consensus statement for sarcoma brachytherapy. *Brachytherapy* 2013;12:179-190.
316. Pisters PW, Harrison LB, Woodruff JM, et al. A prospective randomized trial of adjuvant brachytherapy in the management of low-grade soft tissue sarcomas of the extremity and superficial trunk. *J Clin Oncol* 1994;12:1150-1155.
317. Schupak K, Lane J, Weilep A, et al. The psychofunctional handicap associated with the use of brachytherapy in the treatment of lower extremity high grade soft tissue sarcomas. Proceedings of the 35th Annual ASTRO Meeting. *Int J Radiat Oncol Biol Phys* 1993;27:293.
318. Delannes M, Thomas L, Martel P, et al. Low-dose-rate intraoperative brachytherapy combined with external beam irradiation in the conservative treatment of soft tissue sarcoma. *Int J Radiat Oncol Biol Phys* 2000;47:165-169.
319. Alekhteyar KM, Leung DH, Brennan MF, et al. The effect of combined external beam radiotherapy and brachytherapy on local control and wound complications in patients with high-grade soft tissue sarcomas of the extremity with positive microscopic margin. *Int J Radiat Oncol Biol Phys* 1996;36:321-324.
320. Nag S, Shasha D, Janjan N, et al. The American Brachytherapy Society recommendations for brachytherapy of soft tissue sarcomas. *Int J Radiat Oncol Biol Phys* 2001;49:1033-1043.
321. Ballo MT, Lee AK. Current results of brachytherapy for soft tissue sarcoma. *Curr Opin Oncol* 2003;15:313-318.
322. Arthur DW, Koo D, Zwicker RD, et al. Partial breast brachytherapy after lumpectomy: low-dose-rate and high-dose-rate experience. *Int J Radiat Oncol Biol Phys* 2003;56:681-689.
323. Ott OJ, Potter R, Hammer J, et al. Accelerated partial breast irradiation with iridium-192 multicatheter PDR/HDR brachytherapy. Preliminary results of the German-Austrian multicenter trial. *Strahlenther Onkol* 2004;180:642-649.
324. Wazer DE, Berle L, Graham R, et al. Preliminary results of a phase I/II study of HDR brachytherapy alone for T1/T2 breast cancer. *Int J Radiat Oncol Biol Phys* 2002;53:889-897.
325. Aronowitz JN, Pohar SS, Liu L, et al. Adjuvant high dose rate brachytherapy in the management of soft tissue sarcoma: a dose-toxicity analysis. *Am J Clin Oncol* 2006;29:508-513.
326. Beltrami G, Rudiger HA, Mela MM, et al. Limb salvage surgery in combination with brachytherapy and external beam radiation for high-grade soft tissue sarcomas. *Eur J Surg Oncol* 2008;34:811-816.
327. Llacer C, Delannes M, Minsat M, et al. Low-dose intraoperative brachytherapy in soft tissue sarcomas involving neurovascular structure. *Radiother Oncol* 2006;78:10-16.
328. Levine AM, Coleman C, Horasek S. Stereotactic radiosurgery for the treatment of primary sarcomas and sarcoma metastases of the spine. *Neurosurgery* 2009;64:A54-59.
329. DeLaney TF, Liebsch NJ, Pedlow FX, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. *Int J Radiat Oncol Biol Phys* 2009;74:732-739.
330. Kepka L, DeLaney TF, Suit HD, et al. Results of radiation therapy for unresected soft-tissue sarcomas. *Int J Radiat Oncol Biol Phys* 2005;63:852-859.
331. Tepper JE, Suit HD. Radiation therapy alone for sarcoma of soft tissue. *Cancer* 1985;56:475-479.
332. Slater JD, McNeese MD, Peters LJ. Radiation therapy for unresectable soft tissue sarcomas. *Int J Radiat Oncol Biol Phys* 1986;12:1729-1734.
333. Schwarz R, Krull A, Lessel A, et al. European results of neutron therapy in soft tissue sarcomas. *Recent Results Cancer Res* 1998;150:100-112.
334. Schwartz DL, Einck J, Bellon J, et al. Fast neutron radiotherapy for soft tissue and cartilaginous sarcomas at high risk for local recurrence. *Int J Radiat Oncol Biol Phys* 2001;50:449-456.
335. Sugahara S, Kamada T, Imai R, et al. Carbon ion radiotherapy for localized primary sarcoma of the extremities: results of a phase I/II trial. *Radiother Oncol* 2012;105:226-231.
336. Serizawa I, Kagei K, Kamada T, et al. Carbon ion radiotherapy for unresectable retroperitoneal sarcomas. *Int J Radiat Oncol Biol Phys* 2009;75:1105-1110.
337. Ares C, Hug EB, Lomax AJ, et al. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. *Int J Radiat Oncol Biol Phys* 2009;75:1111-1118.
338. Weber DC, Rutz HP, Bolsi A, et al. Spot scanning proton therapy in the curative treatment of adult patients with sarcoma: the Paul Scherrer institute experience. *Int J Radiat Oncol Biol Phys* 2007;69:865-871.
339. Goffman T, Tochner Z, Glatstein E. Primary treatment of large and massive adult sarcomas with iododeoxyuridine and aggressive hyperfractionated irradiation. *Cancer* 1991;67:572-576.
340. Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. *Oncology* 2003;65 Suppl 2:80-84.
341. Bramwell V, Rousse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma—reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *J Clin Oncol* 1994;12:1137-1149.
342. Alvegard TA, Sigurdsson H, Mouridsen H, et al. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. *J Clin Oncol* 1989;7:1504-1513.
343. Brodowicz T, Schwameis E, Widder J, et al. Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: a prospective randomized feasibility trial. *Sarcoma* 2000;4:151-160.
344. Woll PJ, Reichardt P, Le Cesne A, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. *Lancet Oncol* 2012;13:1045-1054.
345. Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for "high-risk" adult soft-tissue sarcoma. *Eur J Cancer* 2001;37:1096-1103.
346. Antman K, Ryan L, Borden E, et al. Pooled results from three randomized adjuvant studies of doxorubicin versus observation in soft tissue sarcomas: 10 year results and review of the literature. In: Salmon S, ed. *Adjuvant Therapy of Cancer*. Vol 6. Philadelphia: WB Saunders; 1990:529.
347. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. *Lancet* 1997;350:1647-1654.
348. Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. *Cancer* 2008;113:573-581.
349. Edmonson JH, Fleming TR, Ivins JC, et al. Randomized study of systemic chemotherapy following complete excision of nonosseous sarcomas. *J Clin Oncol* 1984;2:1390-1396.

350. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. *Lancet Oncol* 2003;4:429–437.
351. Bonvalot S, Laplanche A, Lejeune F, et al. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? *Ann Oncol* 2005;16:1061–1068.
352. Bonvalot S, de Baere T, Mendiboure J, et al. Hyperthermic pelvic perfusion with tumor necrosis factor-alpha for locally advanced cancers: encouraging results of a phase II study. *Ann Surg* 2012;255:281–286.
353. DeLaney TF, Spiro IJ, Suit HD, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. *Int J Radiat Oncol Biol Phys* 2003;56:1117–1127.
354. Mullen JT, Kobayashi W, Wang JJ, et al. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas. *Cancer* 2012;118:3758–3765.
355. O'Sullivan B, Bell RS. Has "MAID" made it in the management of high-risk soft-tissue sarcoma? *Int J Radiat Oncol Biol Phys* 2003;56:915–916.
356. Kraybill WC, Harris J, Spiro IJ, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. *J Clin Oncol* 2006;24:619–625.
357. Kraybill WC, Harris J, Spiro IJ, et al. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. *Cancer* 2010;116:4613–4621.
358. Eilber FC, Brennan MF, Riedel E, et al. Prognostic factors for survival in patients with locally recurrent extremity soft tissue sarcomas. *Ann Surg Oncol* 2005;12:228–236.
359. Indelicato DJ, Meadows K, Gibbs CP Jr, et al. Effectiveness and morbidity associated with reirradiation in conservative salvage management of recurrent soft-tissue sarcoma. *Int J Radiat Oncol Biol Phys* 2009;73:267–272.
360. Torres MA, Ballo MT, Butler CE, et al. Management of locally recurrent soft-tissue sarcoma after prior surgery and radiation therapy. *Int J Radiat Oncol Biol Phys* 2007;67:1124–1129.
361. Catton C, Davis A, Bell R, et al. Soft tissue sarcoma of the extremity. Limb salvage after failure of combined conservative therapy. *Radiother Oncol* 1996;41:209–214.
362. Moureau-Zabotto L, Thomas L, Bui BN, et al. [Management of soft tissue sarcomas in first isolated local recurrence: a retrospective study of 83 cases]. *Cancer Radiother* 2004;8:279–287.
363. Pearlstone DB, Janjan NA, Feig BW, et al. Re-resection with brachytherapy for locally recurrent soft tissue sarcoma arising in a previously radiated field. *Cancer J Sci Am* 1999;5:26–33.
364. Niewald M, Fleckenstein J, Licht N, et al. Intraoperative radiotherapy (IORT) combined with external beam radiotherapy (EBRT) for soft-tissue sarcomas—a retrospective evaluation of the Homburg experience in the years 1995–2007. *Radiat Oncol* 2009;4:32.
365. Tran PT, Hara W, Su Z, et al. Intraoperative radiation therapy for locally advanced and recurrent soft-tissue sarcomas in adults. *Int J Radiat Oncol Biol Phys* 2008;72:1146–1153.
366. Calvo FA, Sole CV, Cambeiro M, et al. Prognostic value of external beam radiation therapy in patients treated with surgical resection and intraoperative electron beam radiation therapy for locally recurrent soft tissue sarcoma: a multicentric long-term outcome analysis. *Int J Radiat Oncol Biol Phys* 2014;88:143–150.
367. Bonvalot S, Rivoire M, Castaing M, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. *J Clin Oncol* 2009;27:31–37.
368. Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. *J Clin Oncol* 2009;27:24–30.
369. Bevilacqua RG, Rogatko A, Hajdu SI, et al. Prognostic factors in primary retroperitoneal soft-tissue sarcomas. *Arch Surg* 1991;126:328–334.
370. Shibata D, Lewis JJ, Leung DH, et al. Is there a role for incomplete resection in the management of retroperitoneal liposarcomas? *J Am Coll Surg* 2001;193:373–379.
371. Pisters PW, Ballo MT, Fenstermacher MJ, et al. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. *J Clin Oncol* 2003;21:3092–3097.
372. Jones JJ, Catton CN, O'Sullivan B, et al. Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma. *Ann Surg Oncol* 2002;9:346–354.
373. Smith MJ, Ridgway PF, Catton CN, et al. Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: Long-term results of a prospective trial. *Radiother Oncol* 2014;110:165–171.
374. Pawlik TM, Pisters PW, Mikula L, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. *Ann Surg Oncol* 2006;13:508–517.
375. Gunderson LL, Nagorney DM, McIlrath DC, et al. External beam and intraoperative electron irradiation for locally advanced soft tissue sarcomas. *Int J Radiat Oncol Biol Phys* 1993;25:647–656.
376. Petersen IA, Haddock MG, Donohue JH, et al. Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcoma. *Int J Radiat Oncol Biol Phys* 2002;52:469–475.
377. Sindelar WF, Kinsella TJ, Chen PW, et al. Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. *Arch Surg* 1993;128:402–410.
378. Alektiar KM, Hu K, Anderson L, et al. High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. *Int J Radiat Oncol Biol Phys* 2000;47:157–163.
379. Tzeng CW, Fiveash JB, Popple RA, et al. Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma. *Cancer* 2006;107:371–379.
380. Yoon SS, Chen YL, Kirsch DG, et al. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas. *Ann Surg Oncol* 2010;17:1515–1529.
381. De Wever I, Laenen A, Van Limbergen E. Pre-operative irradiation for retroperitoneal liposarcoma: results of a pilot study. *Acta Chir Belg* 2013;113:315–321.
382. European Organisation for Research and Treatment of Cancer. EORTC: Clinical Trials. <http://www.eortc.org/clinical-trials>. Accessed January 24, 2013.
383. Park JO, Qin LX, Prete FP, et al. Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule. *Ann Surg* 2009;250:977–982.
384. Devereux DF, Kent H, Brennan MF. Time dependent effects of adriamycin and x-ray therapy on wound healing in the rat. *Cancer* 1980;45:2805–2810.
385. Shamberger R, Devereux D, Brennan M. The effect of chemotherapeutic agents on wound healing. In: Murphy G, ed. *International Advances in Surgical Oncology*. New York: Alan R. Liss; 1981:15.
386. Meric F, Milas M, Hunt KK, et al. Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. *J Clin Oncol* 2000;18:3378–3383.
387. Simon MA, Nachman J. The clinical utility of preoperative therapy for sarcomas. *J Bone Joint Surg Am* 1986;68:1458–1463.
388. Bujko K, Suit HD, Springfield DS, et al. Wound healing after preoperative radiation for sarcoma of soft tissues. *Surg Gynecol Obstet* 1993;176:124–134.
389. Tseng JF, Ballo MT, Langstein HN, et al. The effect of preoperative radiotherapy and reconstructive surgery on wound complications after resection of extremity soft-tissue sarcomas. *Ann Surg Oncol* 2006;13:1209–1215.
390. O'Sullivan B, Gullane P, Irish J, et al. Preoperative radiotherapy for adult head and neck soft tissue sarcoma: assessment of wound complication rates and cancer outcome in a prospective series. *World J Surg* 2003;27:875–883.
391. Stinson SF, DeLaney TF, Greenberg J, et al. Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcoma. *Int J Radiat Oncol Biol Phys* 1991;21:1493–1499.
392. Alektiar KM, Zelefsky MJ, Brennan MF. Morbidity of adjuvant brachytherapy in soft tissue sarcoma of the extremity and superficial trunk. *Int J Radiat Oncol Biol Phys* 2000;47:1273–1279.
393. Helmsstedter CS, Goebel M, Zlotocki R, et al. Pathologic fractures after surgery and radiation for soft tissue tumors. *Clin Orthop Relat Res* 2001:165–172.
394. Lin PP, Schupak KD, Boland PJ, et al. Pathologic femoral fracture after periosteal excision and radiation for the treatment of soft tissue sarcoma. *Cancer* 1998;82:2356–2365.
395. Holt GE, Griffin AM, Pintilie M, et al. Fractures following radiotherapy and limb-salvage surgery for lower extremity soft-tissue sarcomas. A comparison of high-dose and low-dose radiotherapy. *J Bone Joint Surg Am* 2005;87:315–319.
396. Dickie CI, Parent AL, Griffin AM, et al. Bone fractures following external beam radiotherapy and limb-preservation surgery for lower extremity soft tissue sarcoma: relationship to irradiated bone length, volume, tumor location and dose. *Int J Radiat Oncol Biol Phys* 2009;75:1119–1124.
397. Le Pechoux C, Le Deley MC, Delaloue S, et al. Postoperative radiotherapy in the management of adult soft tissue sarcoma of the extremities: results with two different total dose, fractionation, and overall treatment time schedules. *Int J Radiat Oncol Biol Phys* 1999;44:879–886.
398. Spear MA, Dupuy DE, Park JJ, et al. Tolerance of autologous and allogeneic bone grafts to therapeutic radiation in humans. *Int J Radiat Oncol Biol Phys* 1999;45:1275–1280.
399. Spierer MM, Alektiar KM, Zelefsky MJ, et al. Tolerance of tissue transfers to adjuvant radiation therapy in primary soft tissue sarcoma of the extremity. *Int J Radiat Oncol Biol Phys* 2003;56:1112–1116.
400. Leahy M, Garcia Del Muro X, Reichardt P, et al. Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study. *Ann Oncol* 2012;23:2763–2770.
401. Temple LK, Brennan MF. The role of pulmonary metastasectomy in soft tissue sarcoma. *Semin Thorac Cardiovasc Surg* 2002;14:35–44.
402. Lanza LA, Putnam JB Jr, Benjamin RS, et al. Response to chemotherapy does not predict survival after resection of sarcomatous pulmonary metastases. *Ann Thorac Surg* 1991;51:219–224.
403. Weiser MR, Downey RJ, Leung DH, et al. Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. *J Am Coll Surg* 2000;191:184–190.

404. Judson I, Verweij J, Gelderblom H, et al. Results of a randomised phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study by the EORTC Soft Tissue and Bone Sarcoma Group. *Ann Oncol* 2012;23:ixc28 [abstract LBA27].
405. Ryan CW, Schoffski P, Merimsky O, et al. PICASSO 3: A phase 3 international, randomized, double-blind, placebo-controlled study of doxorubicin (dox) plus palifosfamide (pali) vs. dox plus placebo for patients (pts) in first-line for metastatic soft tissue sarcoma (mSTS) *Eur J Cancer* 2013;49:S759–S892 [abstract 2082].
406. O'Bryan RM, Baker LH, Gottlieb JE, et al. Dose response evaluation of adriamycin in human neoplasia. *Cancer* 1977;39:1940–1948.
407. Steward WP, Verweij J, Somers R, et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *J Clin Oncol* 1993;11:15–21.
408. Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer* 2001;37:870–877.
409. Bramwell VH, Mouridsen HT, Santoro A, et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. *Eur J Cancer Clin Oncol* 1987;23:311–321.
410. Benjamin RS, Legha SS, Patel SR, et al. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. *Cancer Chemother Pharmacol* 1993;31 Suppl 2:S174–S179.
411. Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. *Cancer* 1994;73:2506–2511.
412. Buesa JM, Mouridsen HT, van Oosterom AT, et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. *Ann Oncol* 1991;2:307–309.
413. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 2012;379:1879–1886.
414. Schoffski P, Wolter P, Clement P, et al. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. *Future Oncol* 2007;3:381–392.
415. Lopez-Martin JA, Verweij J, Blay J, et al. An exploratory analysis of tumor growth rate (TGR) variations induced by trabectedin (ecteinascidin-743, ET-743) in patients (pts) with pretreated advanced soft tissue sarcoma (PASTS). *Proc Am Soc Clin Oncol* 2003;22:3293 [abstract].
416. Schoffski P, Dumez H, Wolter P, et al. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. *Expert Opin Pharmacother* 2008;9:1609–1618.
417. Grasso F, Demetri GD, Glay JY, et al. Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas. *J Clin Oncol* 2006;24:9511.
418. Garcia-Carbonero R, Supko JC, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. *J Clin Oncol* 2004;22:1480–1490.
419. Monk BJ, Blessing JA, Street DC, et al. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study. *Gynecol Oncol* 2012;124:48–52.
420. Svancarova L, Blay JY, Judson IR, et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer* 2002;38:556–559.
421. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. *J Clin Oncol* 2011;29:917–924.
422. National Institutes of Health. ClinicalTrials.gov: Chemotherapy followed by ESO-1 lymphocytes and adalimumab to treat metastatic cancer. <http://www.clinicaltrials.gov/ct2/show/NCT00670748>. Accessed November 26, 2013.
423. Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. *J Natl Cancer Inst* 1991;83:926–932.
424. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *J Clin Oncol* 1995;13:1537–1545.
425. Frustaci S, Foladore S, Buonadonna A, et al. Epirubicin and ifosfamide in advanced soft tissue sarcomas. *Ann Oncol* 1993;4:669–672.
426. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. *J Clin Oncol* 1993;11:1276–1285.
427. Edmonson JH, Long HJ, Richardson RL, et al. Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas. *Cancer Chemother Pharmacol* 1985;15:181–182.
428. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. *J Clin Oncol* 1993;11:1269–1275.
429. Verma S, Younus J, Stys-Norman D, et al. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. *Cancer Treat Rev* 2008;34:339–347.
430. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens—a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. *J Clin Oncol* 1999;17:150–157.
431. Struck RF, Schmid SM, Waud WR. Antitumor activity of halogen analogs of phosphoramidate, isophosphoramidate, and triphosphoramidate mustards, the cytotoxic metabolites of cyclophosphamide, ifosfamide, and trofosfamide. *Cancer Chemother Pharmacol* 1994;34:191–196.
432. Zhang J, Tian Q, Zhu YZ, et al. Reversal of resistance to oxazaphosphorines. *Current Cancer Drug Tar* 2006;6:385–407.
433. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. *J Clin Oncol* 2002;20:2824–2831.
434. Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. *J Clin Oncol* 2004;22:1706–1712.
435. Bay JO, Ray-Coquard I, Fayette J, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. *Int J Cancer* 2006;119:706–711.
436. Maki RG, Hensley ML, Wathen JK, et al. A SARC multicenter phase III study of gemcitabine (G) vs. gemcitabine and docetaxel (G+D) in patients (pts) with metastatic soft tissue sarcomas (STS). *J Clin Oncol (Meeting Abstracts)* 2006;24:9514.
437. Pautier P, Bui Nguyen N, Penel N, et al. Final results of a FNCLCC French Sarcoma Group multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS). *J Clin Oncol* 2009;27:(abst 10527).
438. Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. *J Clin Oncol* 2011;29:2528–2533.
439. Ozer H. American Society of Clinical Oncology guidelines for the use of hematopoietic colony-stimulating factors. *Curr Opin Hematol* 1996;3:3–10.
440. Antman KS, Griffin JD, Elias A, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. *N Engl J Med* 1988;319:593–598.
441. Bui BN, Chevallier B, Chevreau C, et al. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. *J Clin Oncol* 1995;13:2629–2636.
442. Kuenen BC, Tabernero J, Baselga J, et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. *Clin Cancer Res* 2003;9:1648–1655.
443. Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. *J Clin Oncol* 2009;27:3148–3153.
444. Singer S, Succi ND, Ambrosini G, et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. *Cancer Res* 2007;67:6626–6636.
445. Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. *J Clin Oncol* 2013;31:2024–2028.
446. Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. *Clin Cancer Res* 2012;18:568–576.
447. Demetri GD, Chawla SP, Ray-Coquard I, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. *J Clin Oncol* 2013;31:2485–2492.
448. National Cancer Institute. FDA approval for pazopanib hydrochloride. <http://www.cancer.gov/cancertopics/druginfo/fda-pazopanibhydrochloride>. Accessed June 26, 2013.
449. Canter RJ, Qin LX, Downey RJ, et al. Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity: a retrospective analysis. *Cancer* 2007;110:2050–2060.
450. Stacchiotti S, Negri T, Libertini M, et al. Sunitinib malate in solitary fibrous tumor (SFT). *Ann Oncol* 2012;23:3171–3179.
451. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. *J Clin Oncol* 2009;27:4188–4196.
452. Dileo P, Morgan JA, Zahrieh D, et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. *Cancer* 2007;109:1863–1869.
453. Hensley ML, Blessing JA, Degeest K, et al. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. *Gynecol Oncol* 2008;109:323–328.



454. Hensley ML, Blessing JA, Mannel R, et al. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. *Gynecol Oncol* 2008;109:329–334.
455. Okuno S, Ryan LM, Edmonson JH, et al. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. *Cancer* 2003;97:1969–1973.
456. Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. *J Clin Oncol* 2001;19:3483–3489.
457. Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). *Oncologist* 2012;17:1213–1220.
458. Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. *Ann Surg* 2007;246:105–113.
459. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC study 62043). *J Clin Oncol* 2009;27:3126–3132.
460. Grier HE. The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors. *Pediatr Clin North Am* 1997;44:991–1004.
461. Baldini EH, Demetri GD, Fletcher CD, et al. Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. *Ann Surg* 1999;230:79–86.
462. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. *Oncologist* 2007;12:1007–1018.
463. Reed NS, Mangioni C, Malmstrom H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). *Eur J Cancer* 2008;44:808–818.
464. Pautier P, Floquet A, Cupissol D, et al. LMS-02: A phase II single-arm multicenter study of doxorubicin in combination with trabectedin as a first-line treatment of advanced uterine leiomyosarcoma (u-LMS) and soft tissue LMS (ST-LMS): First results in patients with u-LMS. *J Clin Oncol* 2013;15:10505 [abstract].
465. Wade K, Quinn MA, Hammond I, et al. Uterine sarcoma: steroid receptors and response to hormonal therapy. *Gynecol Oncol* 1990;39:364–367.
466. Koontz JI, Soreng AL, Nucci M, et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. *Proc Natl Acad Sci U S A* 2001;98:6348–6353.
467. Lee CH, Ou WB, Marino-Enriquez A, et al. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. *Proc Natl Acad Sci U S A* 2012;109:929–934.
468. Chu MC, Mor G, Lim C, et al. Low-grade endometrial stromal sarcoma: hormonal aspects. *Gynecol Oncol* 2003;90:170–176.
469. Sutton C, Blessing JA, Park R, et al. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. *Obstet Gynecol* 1996;87:747–750.
470. Gega M, Yanagi H, Yoshikawa R, et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. *J Clin Oncol* 2006;24:102–105.
471. Merchant NB, Lewis JJ, Woodruff JM, et al. Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. *Cancer* 1999;86:2045–2052.
472. Pires de Camargo V, Keohan ML, D'Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). *Cancer* 2010;116:2258–2265.
473. Patel SR, Benjamin RS. Desmoid tumors respond to chemotherapy: defying the dogma in oncology. *J Clin Oncol* 2006;24:11–12.
474. Okuno SH, Edmonson JH. Combination chemotherapy for desmoid tumors. *Cancer* 2003;97:1134–1135.
475. Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. *Cancer* 1993;72:3244–3247.
476. Skubitz KM, Manivel JC, Clohisey DR, et al. Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors. *Cancer Chemother Pharmacol* 2009;64:635–640.
477. Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. *Ann Surg Oncol* 2009;16:2587–2593.
478. Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. *J Clin Oncol* 2011;29:3553–3558.
479. Crago AM, Denton B, Salas S, et al. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. *Ann Surg* 2013;258:347–353.
480. Constantiniadou A, Jones RL, Scurr M, et al. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. *Eur J Cancer* 2009;45:2930–2934.
481. Seiter K, Kemeny N. Successful treatment of a desmoid tumor with doxorubicin. *Cancer* 1993;71:2242–2244.
482. Weiss AJ, Horowitz S, Lackman RD. Therapy of desmoid tumors and fibromatosis using vinorelbine. *Am J Clin Oncol* 1999;22:193–195.
483. Chugh R, Maki RG, Thomas DG, et al. A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. *J Clin Oncol (Meeting Abstracts)* 2006;24:9515.
484. Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). *J Clin Oncol* 2006;24:1195–1203.
485. Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of Sorafenib against desmoid tumor/deep fibromatosis. *Clin Cancer Res* 2011;17:4082–4090.
486. Spear MA, Jennings LC, Mankin HJ, et al. Individualizing management of aggressive fibromatoses. *Int J Radiat Oncol Biol Phys* 1998;40:637–645.
487. Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. *Int J Radiat Oncol Biol Phys* 1998;42:1007–1014.
488. Brien EW, Terek RM, Geer RJ, et al. Treatment of soft-tissue sarcomas of the hand. *J Bone Joint Surg Am* 1995;77:564–571.
489. Lin PP, Guzel VB, Pisters PW, et al. Surgical management of soft tissue sarcomas of the hand and foot. *Cancer* 2002;95:852–861.
490. Bray PW, Bell RS, Bowen CV, et al. Limb salvage surgery and adjuvant radiotherapy for soft tissue sarcomas of the forearm and hand. *J Hand Surg Am* 1997;22:495–503.
491. Miner TJ, Brennan MF, Jaques DP. A prospective, symptom related, outcomes analysis of 1022 palliative procedures for advanced cancer. *Ann Surg* 2004;240:719–726, discussion 726–727.
492. Yeh JJ, Singer S, Brennan MF, et al. Effectiveness of palliative procedures for intra-abdominal sarcomas. *Ann Surg Oncol* 2005;12:1084–1089.
493. Soyfer V, Corn BW, Kollender Y, et al. Radiation therapy for palliation of sarcoma metastases: a unique and uniform hypofractionation experience. *Sarcoma* 2010:1–4.
494. Flannery T, Kano H, Niranjan A, et al. Gamma knife radiosurgery as a therapeutic strategy for intracranial sarcomatous metastases. *Int J Radiat Oncol Biol Phys* 2010;76:513–519.
495. Stragliotto CL, Karlsson K, Lax I, et al. A retrospective study of SBRT of metastases in patients with primary sarcoma. *Medical Oncol* 2012;29:3431–3439.
496. Dhakal S, Corbin KS, Milano MT, et al. Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival. *Int J Radiat Oncol Biol Phys* 2012;82:940–945.
497. Mehta N, Selch M, Wang PC, et al. Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma. *Sarcoma* 2013;2013:360214.
498. Taylor BS, DeCarolis PL, Angeles CV, et al. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. *Cancer Discov* 2011;1:587–597.
499. Su L, Sampaio AV, Jones KB, et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. *Cancer Cell* 2012;21:333–347.
500. Sakimura R, Tanaka K, Nakatani F, et al. Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. *Int J Cancer* 2005;116:784–792.
501. Benmani-Baiti IM, Machado I, Llombart-Bosch A, et al. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. *Hum Pathol* 2012;43:1300–1307.
502. Sankar S, Bell R, Stephens B, et al. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. *Oncogene* 2013;32:5089–5100.
503. Guijarro MV, Dahiya S, Danielson LS, et al. Dual Pten/Trp53 suppression promotes sarcoma progression by activating Notch signaling. *Am J Pathol* 2013;182:2015–2027.
504. Wang CY, Wei Q, Han I, et al. Hedgehog and Notch signaling regulate self-renewal of undifferentiated pleomorphic sarcomas. *Cancer Res* 2012;72:1013–1022.
505. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. *Nat Rev Drug Discov* 2008;7:771–782.
506. Chang AE, Kinsella T, Glatstein E, et al. Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. *J Clin Oncol* 1988;6:1491–1500.
507. Rosenberg SA, Chang AE, Glatstein E. Adjuvant chemotherapy for treatment of extremity soft tissue sarcomas: review of the National Cancer Institute experience. *Cancer Treat Symp* 1985;3:83–88.
508. Rosenberg SA, Tepper J, Glatstein E, et al. Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. *Cancer* 1983;52:424–434.
509. Glenn J, Kinsella T, Glatstein E, et al. A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk. *Cancer* 1985;55:1206–1214.
510. Glenn J, Sindelar WF, Kinsella T, et al. Results of multimodality therapy of resectable soft-tissue sarcomas of the retroperitoneum. *Surgery* 1985;97:316–325.
511. Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. *J Clin Oncol* 1985;3:1240–1245.

512. Benjamin RS, Terjanian TO, Fenoglio CJ, et al. The importance of combination chemotherapy for adjuvant treatment of high-risk patients with soft-tissue sarcomas of the extremities. In: Salmon SE, ed. *Adjuvant Therapy of Cancer*. Vol 5. Orlando, FL: Grune & Stratton; 1987:735.
513. Lindberg RD, Murphy WK, Benjamin RS, et al. Adjuvant chemotherapy in the treatment of primary soft tissue sarcomas: a preliminary report. *Management of Primary Bone and Soft Tissue Tumors: A Collection of Papers Presented at the Twenty-First Annual Clinical Conference on Cancer, 1976, at the University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas*. Chicago: Year Book Medical, 1977:343.
514. Baker LH. Adjuvant treatment for soft tissue sarcomas. In: Ryan JR, Baker LH, eds. *Recent Concepts in Sarcoma Treatment*. Dordrecht, Netherlands: Kluwer; 1988:130.
515. Lerner HJ, Amato DA, Savlov ED, et al. Eastern Cooperative Oncology Group: a comparison of adjuvant doxorubicin and observation for patients with localized soft tissue sarcoma. *J Clin Oncol* 1987;5:613-617.
516. Antman K, Suit H, Amato D, et al. Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups. *J Clin Oncol* 1984;2:601-608.
517. Wilson RE, Wood WC, Lerner HL, et al. Doxorubicin chemotherapy in the treatment of soft-tissue sarcoma. Combined results of two randomized trials. *Arch Surg* 1986;121:1354-1359.
518. Gherlinzoni F, Bacci C, Picci P, et al. A randomized trial for the treatment of high-grade soft-tissue sarcomas of the extremities: preliminary observations. *J Clin Oncol* 1986;4:552-558.
519. Picci P, Bacci C, Gherlinzoni F, et al. Results of a randomized trial for the treatment of localized soft tissue tumors (STS) of the extremities in adult patients. In: Ryan JR, Baker LH, eds. *Recent Concepts in Sarcoma Treatment*. Dordrecht, Netherlands: Kluwer; 1988:144.
520. Eilber FR, Giuliano AE, Huth JF, et al. Postoperative adjuvant chemotherapy (adriamycin) in high grade extremity soft tissue sarcoma: a randomized prospective trial. In: Salmon SE, ed. *Adjuvant Therapy of Cancer*. Vol 5. Orlando, FL: Grune & Stratton; 1987:719.
521. Ravaud A, Bui NB, Coindre J-M, et al. Adjuvant chemotherapy with CyVAD-IC in high risk soft tissue sarcoma: a randomized prospective trial. In: Salmon SE, ed. *Adjuvant Therapy of Cancer*. Vol 6. Philadelphia: WB Saunders; 1990:556.
522. Piver MS, Lele SB, Marchetti DL, et al. Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas. *J Surg Oncol* 1988;38:233-239.
523. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. *J Clin Oncol* 2001;19:1238-1247.
524. Fakhrai N, Ebm C, Kostler WJ, et al. Intensified adjuvant IFADIC chemotherapy in combination with radiotherapy versus radiotherapy alone for soft tissue sarcoma: long-term follow-up of a prospective randomized feasibility trial. *Wien Klin Wochenschr* 2010;122:614-619.
525. Petrioli R, Coratti A, Correale P, et al. Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma. *Am J Clin Oncol* 2002;25:468-473.
526. Pautier P, Floquet A, Gladieff L, et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. *Ann Oncol* 2013;24:1099-1104.
527. Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. *Cancer* 1983;52:626-632.
528. Muss HB, Bundy B, DiSaia PJ, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). *Cancer* 1985;55:1648-1653.
529. Cruz AB Jr, Thames EA Jr, Aust JB, et al. Combination chemotherapy for soft-tissue sarcomas: a phase III study. *J Surg Oncol* 1979;11:313-323.
530. Schoenfeld DA, Rosenbaum C, Horton J, et al. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. *Cancer* 1982;50:2757-2762.
531. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. *J Clin Oncol* 1987;5:840-850.
532. Borden EC, Amato DA, Edmonson JH, et al. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. *Cancer* 1990;66:862-867.
533. Nielsen OS, Dombrowsky P, Mouridsen H, et al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. *Br J Cancer* 1998;78:1634-1639.
534. Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. *J Clin Oncol* 2007;25:3144-3150.
535. Maurel J, Lopez-Pousa A, de Las Penas R, et al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. *J Clin Oncol* 2009;27:1893-1898.
536. Homesley HD, Filiaci V, Markman M, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. *J Clin Oncol* 2007;25:526-531.